Reuters logo
1 个月内
BRIEF-Newlink Genetics reports positive Phase 1B data for co's IDO pathway inhibitor
2017年6月23日 / 上午11点20分 / 1 个月内

BRIEF-Newlink Genetics reports positive Phase 1B data for co's IDO pathway inhibitor

1 分钟阅读

June 23 (Reuters) - Newlink Genetics Corp:

* Positive phase 1b data for Newlink Genetics’ IDO pathway inhibitor, indoximod, in combination with chemotherapy for patients with newly diagnosed acute myeloid leukemia (aml) presented at the European Hematologic Association (eha) congress in Madrid, Spain Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below